In bladder cancer, the combination of PD-L1 inhibitors and PFD can significantly inhibit bladder cancer progression, potentially by modulating the tumor immune microenvironment and inhibiting tumor cell epithelial-mesenchymal transition (Chen et al., 2024). The gene discussed is CD274; the disease is neoplasm.